Compare Omnicom Group Inc. (OMC) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Omnicom Group Inc. vs Tango Therapeutics Inc. — how do they compare? Omnicom Group Inc. trades at $78.84 (market cap $21.53B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Omnicom Group Inc. is far larger — about 5.7× Tango Therapeutics Inc.'s market cap, and Omnicom Group Inc. pays a 4.08% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Omnicom Group Inc. for 64 Days and Tango Therapeutics Inc. for 0 Days on average.
| OMC | TNGX | |
|---|---|---|
Market Cap | $21.53B | $3.75B |
Volume | 2,515,610 | 9,619,106 |
Sector | Media | Health |
52-Week High | $88.94 | $32.90 |
52-Week Low | $67.27 | $7.50 |
Typical Hold Time | 64 Days | 0 Days |
Enterprise Value | $29.61B | $2.77B |
Dividend Yield | 4.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Omnicom Group (OMC) trades at $78.41, up 1.74% with a bullish technical signal despite mixed earnings results. The company shows strong revenue growth to $17.27B in 2025 but reported a net loss of -$54.50M. Analyst consensus is mixed with 32% buy ratings and a $100.50 price target, while recent news highlights leadership in digital marketing and $3.3B in new H1 2026 billings.
OMC presents a value opportunity with attractive P/S of 0.88 and dividend yield, though high P/E of 212.14 reflects earnings volatility. Key risks include advertising market weakness and elevated debt levels, while AI capabilities and post-Interpublic synergies offer growth catalysts for patient investors.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
